JP2019505553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019505553A5 JP2019505553A5 JP2018543599A JP2018543599A JP2019505553A5 JP 2019505553 A5 JP2019505553 A5 JP 2019505553A5 JP 2018543599 A JP2018543599 A JP 2018543599A JP 2018543599 A JP2018543599 A JP 2018543599A JP 2019505553 A5 JP2019505553 A5 JP 2019505553A5
- Authority
- JP
- Japan
- Prior art keywords
- interferon lambda
- treatment
- use according
- serum
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022140259A JP2022172279A (ja) | 2016-02-19 | 2022-09-02 | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 |
| JP2024125792A JP2024156840A (ja) | 2016-02-19 | 2024-08-01 | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662297759P | 2016-02-19 | 2016-02-19 | |
| US62/297,759 | 2016-02-19 | ||
| PCT/US2017/018466 WO2017143253A1 (en) | 2016-02-19 | 2017-02-17 | Treatment of hepatitis delta virus infection with interferon lambda |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022140259A Division JP2022172279A (ja) | 2016-02-19 | 2022-09-02 | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019505553A JP2019505553A (ja) | 2019-02-28 |
| JP2019505553A5 true JP2019505553A5 (enExample) | 2020-03-26 |
| JP7674628B2 JP7674628B2 (ja) | 2025-05-12 |
Family
ID=59625481
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018543599A Active JP7674628B2 (ja) | 2016-02-19 | 2017-02-17 | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 |
| JP2022140259A Pending JP2022172279A (ja) | 2016-02-19 | 2022-09-02 | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 |
| JP2024125792A Pending JP2024156840A (ja) | 2016-02-19 | 2024-08-01 | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022140259A Pending JP2022172279A (ja) | 2016-02-19 | 2022-09-02 | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 |
| JP2024125792A Pending JP2024156840A (ja) | 2016-02-19 | 2024-08-01 | インターフェロンラムダによるデルタ型肝炎ウイルス感染の処置 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10953072B2 (enExample) |
| EP (2) | EP3416675B9 (enExample) |
| JP (3) | JP7674628B2 (enExample) |
| KR (1) | KR20180110127A (enExample) |
| CN (1) | CN108883156A (enExample) |
| CY (1) | CY1124220T1 (enExample) |
| DK (1) | DK3416675T3 (enExample) |
| ES (2) | ES2874592T3 (enExample) |
| HR (1) | HRP20210862T1 (enExample) |
| HU (1) | HUE055343T2 (enExample) |
| LT (1) | LT3416675T (enExample) |
| PL (1) | PL3416675T3 (enExample) |
| PT (1) | PT3416675T (enExample) |
| RS (1) | RS61944B1 (enExample) |
| SI (1) | SI3416675T1 (enExample) |
| SM (1) | SMT202100335T1 (enExample) |
| WO (1) | WO2017143253A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11311519B2 (en) | 2014-05-01 | 2022-04-26 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| HUE054068T2 (hu) | 2015-04-21 | 2021-08-30 | Eiger Biopharmaceuticals Inc | Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények |
| PL3416675T3 (pl) * | 2016-02-19 | 2021-10-11 | Eiger Biopharmaceuticals, Inc. | Leczenie zakażenia wirusem zapalenia wątroby typu delta za pomocą interferonu lambda |
| GB201621728D0 (en) * | 2016-12-20 | 2017-02-01 | Ucb Biopharma Sprl | Methods |
| KR20210049125A (ko) * | 2018-08-23 | 2021-05-04 | 아이거 바이오파마슈티컬스 인코포레이티드 | 인터페론 람다를 이용한 델타 간염 바이러스 감염의 치료 |
| AU2020312735A1 (en) | 2019-07-18 | 2021-12-16 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| KR20210023737A (ko) * | 2019-08-21 | 2021-03-04 | 한국과학기술원 | 신규 인터페론 람다 변이체 및 이의 제조방법 |
| KR20220083764A (ko) * | 2019-10-16 | 2022-06-20 | 아이거 바이오파마슈티컬스 인코포레이티드 | 델타 간염 바이러스 감염을 치료하는 방법 |
| WO2021159027A1 (en) * | 2020-02-06 | 2021-08-12 | Eiger Biopharmaceuticals, Inc. | Treatment of coronavirus infection with interferon lambda |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100448993C (zh) | 2000-06-30 | 2009-01-07 | 津莫吉尼蒂克斯公司 | 干扰素样蛋白质Zcyto21 |
| US7038032B2 (en) | 2001-04-20 | 2006-05-02 | Zymogenetics, Inc. | Cytokine protein family |
| AU2003286624B2 (en) | 2002-10-23 | 2008-11-13 | Bristol-Myers Squibb Company | Methods for treating viral infection using IL-28 and IL-29 |
| CA2520148A1 (en) | 2003-04-01 | 2004-12-23 | Intermune, Inc. | Compositions and methods for treating coronavirus infection and sars |
| ES2303132T3 (es) | 2003-08-07 | 2008-08-01 | Zymogenetics, Inc. | Preparaciones homogeneas de il-29. |
| JP4896005B2 (ja) | 2004-04-02 | 2012-03-14 | ザイモジェネティクス リミテッド ライアビリティ カンパニー | Ｉｌ−２８およびｉｌ−２９システイン変異体を用いるウイルス感染を治療するための方法 |
| WO2006076014A2 (en) | 2004-04-30 | 2006-07-20 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Interferon-alpha constructs for use in the treatment of sars |
| JP4987001B2 (ja) | 2005-07-20 | 2012-07-25 | ザイモジェネティクス リミテッド ライアビリティ カンパニー | 癌および自己免疫障害を処置するためのｉｌ２８およびｉｌ２９の短縮型システイン変異体の使用法 |
| US20070053933A1 (en) | 2005-07-20 | 2007-03-08 | Sheppard Paul O | IL28 and IL29 TRUNCATED CYSTEINE MUTANTS AND ANTIVIRAL METHODS OF USING SAME |
| DE602006018969D1 (de) | 2005-10-04 | 2011-01-27 | Bristol Myers Squibb Co | Herstellung und reinigung von il-29 |
| CN102886052B (zh) | 2006-09-14 | 2014-07-30 | 迈德詹尼克斯医疗以色列有限公司 | 长效药物制剂 |
| CA2720168C (en) * | 2008-04-04 | 2024-04-30 | David B. Weiner | Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same |
| WO2011088126A2 (en) | 2010-01-13 | 2011-07-21 | Eiger Biopharmaceuticals, Inc. | Treatment of viral infection with prenyltransferase inhibitors |
| RS53911B1 (sr) | 2011-04-01 | 2015-08-31 | Novartis Ag | Tretman u infekciji virusom hepatitis b zasebno ili u kombinaciji sa hepatitis delta virusom i bolesti jetre koje ih prate |
| EA030381B1 (ru) * | 2011-06-14 | 2018-07-31 | Глоубиммьюн, Инк. | Иммунотерапевтическая композиция, ее применения и способы лечения или профилактики инфекции, вызванной вирусом гепатита дельта |
| CN103228792A (zh) * | 2011-08-25 | 2013-07-31 | 纳诺亘医药生物科技公司 | PEG-干扰素λ1结合物 |
| US8454947B1 (en) | 2012-03-01 | 2013-06-04 | Nanogen Pharmaceutical Biotechnology | PEG-interferon lambda 1 conjugates |
| NZ705730A (en) * | 2012-08-30 | 2016-06-24 | Replicor Inc | Methods for the treatment of hepatitis b and hepatitis d infections |
| PE20151604A1 (es) | 2012-11-02 | 2015-11-04 | Pharmacyclics Llc | Terapia adyuvante con inhibidores de quinasa de la familia tec |
| ES2728405T3 (es) * | 2014-05-01 | 2019-10-24 | Eiger Biopharmaceuticals Inc | Tratamiento de la infección por virus de hepatitis delta |
| US10076512B2 (en) * | 2014-05-01 | 2018-09-18 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| JP2017536403A (ja) | 2014-12-04 | 2017-12-07 | アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | デルタ肝炎ウイルス感染の治療 |
| HUE054068T2 (hu) | 2015-04-21 | 2021-08-30 | Eiger Biopharmaceuticals Inc | Lonafarnibot és Ritonavirt tartalmazó gyógyszerkészítmények |
| EP3858352A1 (en) * | 2015-11-04 | 2021-08-04 | Eiger Biopharmaceuticals, Inc. | Treatment of hepatitis delta virus infection |
| PL3416675T3 (pl) * | 2016-02-19 | 2021-10-11 | Eiger Biopharmaceuticals, Inc. | Leczenie zakażenia wirusem zapalenia wątroby typu delta za pomocą interferonu lambda |
| GB201621728D0 (en) | 2016-12-20 | 2017-02-01 | Ucb Biopharma Sprl | Methods |
| KR20210049125A (ko) | 2018-08-23 | 2021-05-04 | 아이거 바이오파마슈티컬스 인코포레이티드 | 인터페론 람다를 이용한 델타 간염 바이러스 감염의 치료 |
| WO2021055714A1 (en) | 2019-09-19 | 2021-03-25 | Eip Pharma, Inc. | Compositions and methods for treating prion disease |
| WO2021159027A1 (en) | 2020-02-06 | 2021-08-12 | Eiger Biopharmaceuticals, Inc. | Treatment of coronavirus infection with interferon lambda |
-
2017
- 2017-02-17 PL PL17753966T patent/PL3416675T3/pl unknown
- 2017-02-17 ES ES17753966T patent/ES2874592T3/es active Active
- 2017-02-17 KR KR1020187026586A patent/KR20180110127A/ko not_active Ceased
- 2017-02-17 EP EP17753966.5A patent/EP3416675B9/en active Active
- 2017-02-17 CN CN201780020097.4A patent/CN108883156A/zh active Pending
- 2017-02-17 HU HUE17753966A patent/HUE055343T2/hu unknown
- 2017-02-17 JP JP2018543599A patent/JP7674628B2/ja active Active
- 2017-02-17 RS RS20210703A patent/RS61944B1/sr unknown
- 2017-02-17 SM SM20210335T patent/SMT202100335T1/it unknown
- 2017-02-17 WO PCT/US2017/018466 patent/WO2017143253A1/en not_active Ceased
- 2017-02-17 SI SI201730795T patent/SI3416675T1/sl unknown
- 2017-02-17 HR HRP20210862TT patent/HRP20210862T1/hr unknown
- 2017-02-17 EP EP21164362.2A patent/EP3957319B1/en active Active
- 2017-02-17 PT PT177539665T patent/PT3416675T/pt unknown
- 2017-02-17 US US15/999,239 patent/US10953072B2/en active Active
- 2017-02-17 DK DK17753966.5T patent/DK3416675T3/da active
- 2017-02-17 ES ES21164362T patent/ES3008560T3/es active Active
- 2017-02-17 LT LTEP17753966.5T patent/LT3416675T/lt unknown
-
2021
- 2021-02-18 US US17/178,424 patent/US12508297B2/en active Active
- 2021-06-10 CY CY20211100511T patent/CY1124220T1/el unknown
-
2022
- 2022-09-02 JP JP2022140259A patent/JP2022172279A/ja active Pending
-
2024
- 2024-08-01 JP JP2024125792A patent/JP2024156840A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019505553A5 (enExample) | ||
| Liaw | Therapy of chronic hepatitis B: current challenges and opportunities | |
| HRP20210862T1 (hr) | Liječenje infekcije hepatitis delta virusom pomoću interferona lambda | |
| JP2013522302A5 (enExample) | ||
| WO2018087345A1 (en) | COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON | |
| Defresne et al. | Chronic hepatitis B in children: therapeutic challenges and perspectives | |
| WO2021053126A1 (en) | Method of treating hbv infection using a core protein allosteric modulator | |
| Tanwandee et al. | Efficacy and Safety of Entecavir Treatment of Chronic Hepatitis B Patients in Real-world clinical Practice: 968 | |
| Saltik-Temizel et al. | Lamivudine and high-dose interferon-α combination therapy for naive children with chronic hepatitis B infection | |
| JP2005505582A (ja) | ヒトモノクロナール抗体によるｂ型肝炎ウイルス感染の治療 | |
| Yüce et al. | Prolonged interferon α treatment in children with chronic hepatitis B | |
| EP3999069B1 (en) | Synergistic effect of eyp001 and pegylated ifn-alpha for the treatment of hbv infection | |
| Wang et al. | Safety, tolerability, and hepatitis B surface antigen reduction of HT-101 in chronic hepatitis B patients: preliminary results from a phase Ⅰ b study | |
| Hu et al. | A First-in-patient phase ib study of a hepatitis b virus (HBV) neutralizing antibody hh-003 in treatment naive participants with HbeAg-positive chronic hbv infection | |
| Yuen et al. | Preliminary safety and efficacy of the combination therapy of BRII-835 and BRII-179 treating chronic HBV infection | |
| Ozaras et al. | Treating hepatitis B virus/hepatitis C virus coinfected patients with direct‐acting hepatitis C virus antivirals only is not safe | |
| Šmahelová et al. | Novel autophagy inducer inhibits hepatitis B virus S antigen secretion | |
| Liang et al. | Vebicorvir, entecavir, and pegylated interferon in patients with hepatitis B e antigen positive chronic hepatitis B virus infection: findings from a phase 2, randomized open-label study in China | |
| HK1262528A1 (en) | Diazabicyclo compounds for use in the treatment and/or prevention of diseases or conditions associated with hepatitis viruses | |
| HK1262528B (en) | Diazabicyclo compounds for use in the treatment and/or prevention of diseases or conditions associated with hepatitis viruses | |
| Fiore et al. | Side effects of antiviral drugs used for the treatment of HBV/HDV viruses from a multidisciplinary perspective | |
| Potthoff et al. | 853 THE HEP-NET B/C CO-INFECTION TRIAL: A PROSPECTIVE MULTICENTER STUDY TO INVESTIGATE THE EFFICACY OF PEGYLATED INTERFERON-A2B AND RIBAVIRIN IN PATIENTS WITH HBV/HCV CO-INFECTION | |
| Stanzione et al. | HBsAg seroconversion after pegylated interferon alfa 2a rescue in a lamivudine-resistant patient with HBeAg-negative chronic hepatitis B and favourable IL28-B genotype | |
| Pawlotsky | Drug resistance: prevalence and clinical implications during the treatment of chronic hepatitis C infection | |
| Yatsuji et al. | Antiviral Therapy for Chronic Hepatitis B |